KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Short term Debt (2016 - 2025)

Historic Short term Debt for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $1.8 billion.

  • Teva Pharmaceutical Industries' Short term Debt rose 218.98% to $1.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.8 billion, marking a year-over-year increase of 218.98%. This contributed to the annual value of $1.8 billion for FY2025, which is 218.98% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Short term Debt stood at $1.8 billion, which was up 218.98% from $24.0 million recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Short term Debt registered a high of $3.5 billion during Q2 2021, and its lowest value of $24.0 million during Q3 2025.
  • Moreover, its 5-year median value for Short term Debt was $1.9 billion (2023), whereas its average is $1.9 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Short term Debt soared by 19912.02% in 2024 and then crashed by 9906.98% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Short term Debt (Quarter) stood at $1.4 billion in 2021, then soared by 47.9% to $2.1 billion in 2022, then fell by 20.72% to $1.7 billion in 2023, then rose by 6.52% to $1.8 billion in 2024, then rose by 2.19% to $1.8 billion in 2025.
  • Its Short term Debt stands at $1.8 billion for Q4 2025, versus $24.0 million for Q3 2025 and $464.0 million for Q2 2025.